Cover Image

Synthesis and evaluation of cerebroprotective activity of novel 6,7-dimethoxyquinazolin-4(3H)-one derivatives containing residues of amino acids and dipeptides

Alexey S. Chiriapkin, Ivan P. Kodonidi, Dmitry I. Pozdnyakov


Neurodegenerative processes of the central nervous system are an important socially significant problem of modern society. They cause many diseases, such as Alzheimer's disease and cerebral ischemia, which significantly reduce the quality of human life and can lead to disability or death. The aim of this study was to synthesize novel 6,7-dimethoxyquinazolin-4(3H)-one derivatives with the remains of neuroactive amino acids and dipeptides in order to investigate their cerebroprotective properties. As a result of the study, 13 novel 6,7-dimetho-xyquinazolin-4(3H)-one derivatives were synthesized. Cerebral ischemia in rats was reproduced by irreversible right-sided occlusion of the middle cerebral artery using the Tamura method, and the area of brain necrosis was evaluated. Cognitive functions were evaluated in the Y-maze test. Among the studied quinazolinone derivatives, compounds 3i, 3j and 3k have the most pronounced cerebrotropic activity, which is not inferior to ethylmethylhydroxypyridine succinate in terms of pharmacological activity, making them promising objects for further research.


quinazolinones; synthesis; medicinal chemistry; cerebroprotective activity; ischemia; amino acids; dipeptides

Full Text:



Lin YF, Smith AV, Aspelund T, Betensky RA, Smoller, JW, Gudnason V, launer LJ, Blacker D. Genetic overlap between vascular pathologies and Alzheimer’s dementia and poten-tial causal mechanisms. Alzheimer’s Dementia. 2019;15(1):65–75. doi:10.1016/j.jalz.2018.08.002

Chiriapkin AS, Kodonidi IP, Pozdnyakov DI, Glushko AA. Synthesis, in vitro and docking studies of 2-substituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine-4(3H)-one derivatives as agents for the treatment of Alz-heimer's disease. Chim Techno Acta. 2022;9(2):20229204. doi:10.15826/chimtech.2022.9.2.04

Capizzi A, Woo J, Verduzco-Gutierrez M. Traumatic Brain Injury. Med Clin North Am. 2020;104(2):213–238. doi:10.1016/j.mcna.2019.11.001

Danics K, Forrest SL, Kapas I, Erber I, Schmid S, Törő K, Majtenyi K, Kovacs GG. Neurodegenerative proteinopathies associated with neuroinfections. J Neural Transm. 2021;128:1551–1566. doi:10.1007/s00702-021-02371-7

Mishchenko O, Palagina N. Experimental research of cere-broprotective activity of the new 4-aminobutatanoic acid derivative. EUREKA Health Sci. 2021;3:95–100. doi:10.21303/2504-5679.2021.001851

Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of is-chemic brain damage. Neuropharmacol. 2008;55(3):310–318. doi:10.1016/j.neuropharm.2008.01

Pasala PK, Shaik RA, Rudrapal |M, Khan J, Alaidarous MA, Khairnar SJ, Bendale AR, Naphade VD, Sahoo RK, Zothantluanga JH, Walode SG. Cerebroprotective effect of Aloe Emodin: In silico and in vivo studies. Saudi J Biol Sci.2022;29(2):998–1005. doi:10.1016/j.sjbs.2021.09.077

Sepehri N, Iraji A, Yavari A, Asgari MS, Zamani S, Hosseini S, Bahadorikhalili S, Pirhadi S, Larijani B, Khoshneviszadeh M, Hamedifar H, Mahdavi M, Khoshneviszadeh M. The nat-ural-based optimization of kojic acid conjugated to differ-ent thio-quinazolinones as potential anti-melanogenesis agents with tyrosinase inhibitory activity. Bioorg Med Chem. 2021;36:116044. doi:10.1016/j.bmc.2021.116044

Soliman AM, Karam HM, Mekkawy MH, Ghorab MM. Anti-oxidant activity of novel quinazolinones bearing sulfona-mide: Potential radiomodulatory effects on liver tissues via NF-κB/ PON1 pathway. Eur J Med Chem. 2020;197:112333. doi:10.1016/j.ejmech.2020.112333

Soliman AM, Mekkawy MH, Karam HM, Higgins M, Dinko-va-Kostova AT, Ghorab MM. Novel iodinated quinazoli-nones bearing sulfonamide as new scaffold targeting radia-tion induced oxidative stress. Bioorg Med Chem Lett. 2021;42:128002. doi:10.1016/j.bmcl.2021.128002

Anwar A, Shahbaz MS, Saad SM, Kanwal, Khan KM, Siddiqui R, Khan NA. Novel antiacanthamoebic compounds belong-ing to quinazolinones. Eur J Med Chem. 2019;182:111575. doi:10.1016/j.ejmech.2019.111575

Hekal MH, Abu El-Azm FSM. New potential antitumor quinazolinones derived from dynamic 2-undecyl benzoxa-zinone: Synthesis and cytotoxic evaluation. Synth Com-mun. 2018;48(18):2391–2402. doi:10.1080/00397911.2018.1490433

Ugale VG, Bari SB, Khadse SC, Reddy PN, Bonde CG, Chaudhari PJ. Exploring quinazolinones as anticonvulsants by molecular fragmentation approach: structural optimiza-tion, synthesis and pharmacological evaluation studies. Chem Sel. 2020;5(10):2902–2912. doi:10.1002/slct.201904776

Akyüz G. Synthesis and urease inhibition studies of some new quinazolinones. J Heterocycl Chem. 2021;58(5):1164–1170. doi:10.1002/jhet.4247

Sakr A, Rezq S, Ibrahim SM, Soliman E, Baraka MM, Romero DG, Kothayer H. Design and synthesis of novel quinazoli-nones conjugated ibuprofen, indole acetamide, or thioace-tohydrazide as selective COX-2 inhibitors: anti-inflammatory, analgesic and anticancer activities. J Enzym Inhib Med Chem. 2021;36(1):1810–1828. doi:10.1080/14756366.2021.1956912

Sudula SR, Jala R, Siddoju K, Ega JK. One pot synthesis of some new N-allyl and N-benzyl quinazolinones and their anti-inflammatory activity. J Indian Chem Soc. 2021;98(3):100033. doi:10.1016/j.jics.2021.100033

Thorat DB, Shivkumar B, Rao N, Mohankumar KM. Synthe-sis and evaluation of new 4(3H)-quinazolinones deriva-tives as potential anti-inflammatory agents. Asian J Res Pharmut Sci. 2021;11(3):213–218. doi:10.52711/2231-5659.2021.00034

Deshineni RGAC, Banothu J, Velpula R, Chellamella G. Syn-thesis, anticancer and antibacterial evaluation of novel 1,3-disubstituted-1H-pyrazole-4-yl-methylene embedded fused thiazolo[2,3-b]quinazolinones. Chem Data Collect. 2020;30:100546. doi:10.1016/j.cdc.2020.100546

Patel HM, Noolvi MN, Shirkhedkar AA, Kulkarni AD, Pardeshi CV, Surana SJ. Anti-convulsant potential of quinazolinones. RSC Adv. 2016:6(50):44435–44455. doi:10.1039/C6RA01284A

Neupane R, Malla S, Abou-Dahech MS, Balaji S, Kumari S, Waiker DK, Moorthy NSHN, Trivedi P, Ashby CR Jr., Karthikeyan C, Tiwari AK. Antiproliferative Efficacy of N-(3-chloro-4-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine, DW-8, in colon cancer cells is mediated by intrinsic apoptosis. Mol. 2021;26(15):4417. doi:10.3390/molecules26154417

Saul S, Huang P-T, Einav S, Asquith CRM. Identification and evaluation of 4-anilinoquin(az)online as potent inhibitors of both dengue virus (DENV) and Venezuelan equine en-cephalitis virus (VEEV). Bioorg Med Chem Lett. 2021;52(15):128407. doi:10.1016/j.bmcl.2021.128407

Yao D, Li C, Jiang J, Huang J, Wang J, He Z, Zhang J. Design, synthesis and biological evaluation of novel HDAC Inhibi-tors with improved pharmacokinetic profile in breast can-cer. Eur J Med Chem. 2020;205:112648. doi:10.1016/j.ejmech.2020.112648

Nunes PSG, da Silva G, Nascimento S, Mantovani SP, de Andrade P, Bernardes ES, Kawano DF, Leopoldino AM, Car-valho I. Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole-quinazolines as anti-proliferative agents displaying ERK inhibitory activity. Bioorg Chem. 2021;113:104982. doi:10.1016/j.bioorg.2021.104982

Mizukawa Y, Ikegami-Kawai M, Horiuchi M, Kaiser M, Kojima M, Sakanoue S, Miyagi S, Chick CN, Togashi H, Tsu-baki M, Ihara M, Usuki T, Itoh I. Quest for a potent antima-larial drug lead: Synthesis and evaluation of 6,7-dimethoxyquinazoline-2,4-diamines. Bioorg Med Chem. 2021;33:116018. doi:10.1016/j.bioorg.2021.104982

Prinsloo IF, Zuma NH, Aucamp J, N’Da DD. Synthesis and in vitro antileishmanial efficacy of novel quinazolinone de-rivatives. Chem Biol Drug Des. 2021;97:383–398. doi:10.1111/cbdd.13790

Chang X, Sun D, Shi D, Wang G, Chen Y, Zhang K, Tan H, Liu J, Liu B, Ouyang L. Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy. Acta Pharm Sinica B. 2021;11(1):156–180. doi:10.1016/j.apsb.2020.06.003

Chen J-N, Li T, Chen L, Qin T-S, Sun Y-X, Chen C-T, He Y-Z, Liu G, Yao D, Wei Y, Li Q-Y, Zhang G-J. Synthesis and in vitro anti-bladder cancer activity evaluation of quinazoli-nyl-arylurea derivatives. Eur J Med Chem. 2020;205:112661. doi:10.1016/j.ejmech.2020.112661

Gusev EI, Skvortsova VI, Dambinova SA, Raevskiy KS, Ale-kseev AA, Bashkatova VG, Kovalenko AV, Kudrin VS, Ya-kovleva EV. Neuroprotective effects of glycine for therapy of acute ischaemic stroke. Cerebrovasc Dis. 2000;10(1):49–60. doi:10.1159/000016025

Kodonidi IP, Chiriapkin AS, Tworowski DE. Molecular de-sign of N-acyl derivatives of 2-(2-oxopyrolidin-1-yl)-acetamide with GABA-ergic and glutamatergic activities. Pharm Pharmacol. 2021;9(1):84–97. doi:10.19163/2307-9266-2021-9-1-84-97

Brenneman DE, Gozes I. A femtomolar-acting neuroprotec-tive peptide.J Clin Invest. 1996;97(10):2299–2307. doi:10.1172/JCI118672

Gozes I, Perl O, Giladi E, Davidson A, Ashur-Fabian O, Ru-binraut S, Fridkin M. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: Neuropro-tective drug design. Proceed Nat Acad Sci. 1999;96(7):4143–4148. doi:10.1073/pnas.96.7.4143

Meloni BP, Mastaglia FL, Knuckey NW. Cationic Arginine-Rich Peptides (CARPs): A novel class of neuroprotective agents with a multimodal mechanism of action. Front Neu-rol. 2020;11:108. doi:10.3389/fneur.2020.00108

Edwards AB, Anderton RS, Knuckey NW, Meloni BP. Charac-terisation of neuroprotective efficacy of modified poly-arginine-9 (R9) peptides using a neuronal glutamic acid excitotoxicity model. Mol Cell Biochem. 2017;426:75–85. doi:10.1007/s11010-016-2882-z

Shashoua VE, Adams DS, Boyer-Boiteau A, Cornell-Bell A, Li F, Fisher M. Neuroprotective effects of a new synthetic pep-tide, CMX-9236, in in vitro and in vivo models of cerebral ischemia. Brain Research. 2003;963(1–2):214–223. doi:10.1016/S0006-8993(02)04058-1

Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M ,Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emer-son M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. doi:10.1371/journal.pbio.3000410

Tamura A, Graham DI, McCulloch J, Teasdale GM. Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following mid-dle cerebral artery occlusion. J Cereb Blood Flow Metab. 1981;1(1):53–60. doi:10.1038/jcbfm.1981.6

Pozdnyakov DI, Rukovitsina VM, Abaev VT, Oganesyan ET, Larskii MV. Effect of 3-[(е)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-3-оксопроп-1-енил]-6-methoxy-chrome-4-one on oxidative status of brain tissue under conditions of cerebral ischemia. Eksperimental'naya i Klinicheskaya Farmakologiya. 2021;84(2):3–7. doi:10.30906/0869-2092-2021-84-3-3-7

Amani M, Zolghadrnasab M, Salari AA. NMDA receptor in the hippocampus alters neurobehavioral phenotypes through inflammatory cytokines in rats with sporadic Alz-heimer-like disease. Physiol Behav. 2019;202:52–61. doi:10.1016/j.physbeh.2019.01.005

Ovakimyan АG, Bicherov АА, Kodonidi IP, Oganesyan EТ, Manvelyan EА, Bicherov АV, Tyurin RV, Zaychenko SB, Manvelyan ММ. Prediction, synthesis and study of dopha-minergic activity of hydroxy- and methoxyphenyl deriva-tives of 4-(3)quinazolinone. Modern problems of science and education. 2015;2–2:511.

Rabinstein AA. Update on Treatment of Acute Ischemic Stroke. Continuum (Minneap Minn). 2020;26(2):268–286. doi:10.1212/CON.0000000000000840

Angeloni C, Vauzour D. Natural Products and Neuroprotec-tion. Int J Mol Sci. 2019;20(22):5570. doi:10.3390/ijms20225570

Pozdnyakov DI, Zolotykh DS, Larsky MV. Correction of mito-chondrial dysfunction by succinic acid derivatives under experimental cerebral ischemia conditions. Current Issues in Pharmacy and Medical Sciences. 2021;34(1):42–48. doi:10.2478/cipms-2021-0008

Pozdnyakov DI, Voronkov AV, Rukovitsynа VM. Chromon-3-aldehyde derivatives restore mitochondrial function in rat cerebral ischemia. Iran J Basic Med Sci. 2020;23(9):1172–1183. doi:10.22038/ijbms.2020.46369.10710

Kim JS, Lee KB, Park J-H, Sung SM, Oh K, Kim E-G, Chang D-i, Hwang YH, Lee E-J, Kim W-K, Ju C, Kim BS, Ryu J-M. Safe-ty and Efficacy of Otaplimastat in Patients with Acute Is-chemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. Ann Neurol. 2020;87:233–245. doi:10.1002/ana.25644

Lyden P, Pryor KE, Coffey CS, et al. Final results of the RHAPSODY trial: a multicenter, phase 2 trial using a con-tinual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasmino-gen activator, mechanical thrombectomy or both in moder-ate to severe acute ischemic stroke. Ann Neurol 2019;85:125–136. doi:10.1002/ana.25383

Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomized controlled trial. The Lancet. 2020;395:878–887. doi:10.1016/S0140-6736(20)30258-0


Copyright (c) 2022 Alexey S. Chiriapkin, Ivan P. Kodonidi, Dmitry I. Pozdnyakov

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Scopus logo WorldCat logo DOAJ logo CAS logo BASE logo eLibrary logo

Chimica Techno Acta, 2014-2024
ISSN 2411-1414 (Online)
Copyright Notice